On the opportunity front, emerging markets with large diabetic populations, increasing acceptance of biosimilars in developed countries, advancements in biomanufacturing technologies, and the potential for new indications beyond diabetes and obesity (such as cardiovascular and neurodegenerative diseases) present significant growth potential
Current analyses indicate that the cost of tirzepatide is not regarded as cost-effective at its current price level, requiring a notable decrease of about 30.5% to meet cost-effectiveness criteria
At HMR, our goal is to empower you with the tools, knowledge, and skills to be successful in achieving your weight and health goals
In Phase 2 trials, retatrutide produced approximately 24% mean weight loss at 48 weeks at 12 mg, compared with about 22.5% for tirzepatide at 15 mg in the SURMOUNT-1 trial though direct head-to-head data is not yet available
Once you have these high-quality components, you're ready to proceed